Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5196523
Max Phase: Preclinical
Molecular Formula: C91H139N27O28S5
Molecular Weight: 2219.61
Associated Items:
ID: ALA5196523
Max Phase: Preclinical
Molecular Formula: C91H139N27O28S5
Molecular Weight: 2219.61
Associated Items:
Canonical SMILES: CSCC[C@H](N)C(=O)N[C@H]1CSCC(=O)CSC[C@@H](C(=O)N[C@H]2CSCC(=O)CSC[C@@H](C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]3CCCN3C2=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC1=O
Standard InChI: InChI=1S/C91H139N27O28S5/c1-44(2)30-56-77(133)112-62(82(138)113-63-42-150-38-48(123)39-151-43-64(88(144)118-28-11-18-67(118)89(145)146)114-85(141)71(45(3)121)115-76(132)53(15-8-25-100-91(97)98)102-74(130)55(20-22-69(94)125)105-83(139)65-16-10-27-117(65)87(63)143)41-149-37-47(122)36-148-40-61(111-72(128)50(92)23-29-147-4)81(137)109-59(34-119)79(135)103-52(14-7-24-99-90(95)96)73(129)104-54(19-21-68(93)124)75(131)107-57(31-46-33-101-51-13-6-5-12-49(46)51)78(134)108-58(32-70(126)127)86(142)116-26-9-17-66(116)84(140)110-60(35-120)80(136)106-56/h5-6,12-13,33,44-45,50,52-67,71,101,119-121H,7-11,14-32,34-43,92H2,1-4H3,(H2,93,124)(H2,94,125)(H,102,130)(H,103,135)(H,104,129)(H,105,139)(H,106,136)(H,107,131)(H,108,134)(H,109,137)(H,110,140)(H,111,128)(H,112,133)(H,113,138)(H,114,141)(H,115,132)(H,126,127)(H,145,146)(H4,95,96,99)(H4,97,98,100)/t45-,50+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,71+/m1/s1
Standard InChI Key: UJIXDVQZFYYXNE-QWDQECCDSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2219.61 | Molecular Weight (Monoisotopic): 2217.8886 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Gonschorek P, Zorzi A, Maric T, Le Jeune M, Schüttel M, Montagnon M, Gómez-Ojea R, Vollmar DP, Whitfield C, Reymond L, Carle V, Verma H, Schilling O, Hovnanian A, Heinis C.. (2022) Phage Display Selected Cyclic Peptide Inhibitors of Kallikrein-Related Peptidases 5 and 7 and Their In Vivo Delivery to the Skin., 65 (14.0): [PMID:35653695] [10.1021/acs.jmedchem.2c00306] |
Source(1):